Significance of Vascular Nitric Oxide Synthase Pathways in Coronary Artery Disease A Multiple-Level Biomarker Strategy⁎⁎Editorials published in the Journal of American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. by Kelm, Malte
ES
O
i
A
M
A
C
r
t
i
n
a
w
i
d
o
d
r
f
e
t
l
r
p
a
s
t
p
i
G
c
(
a
T
e
c
t
o
i
u
v
A
a
Journal of the American College of Cardiology Vol. 48, No. 6, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
Pa
i
i
C
G
n
c
n
t
t
(
o
a
a
u
p
e
e
(
r
h
T
p
p
b
(
s
h
r
o
t
t
S
s
t
i
s
q
a
a
N
i
e
f
o
w
l
t
l
e
t
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.028DITORIAL COMMENT
ignificance of Vascular Nitric
xide Synthase Pathways
n Coronary Artery Disease
Multiple-Level Biomarker Strategy*
alte Kelm, MD, FESC
achen, Germany
oronary artery disease (CAD) is a polygenic disorder
epresenting the major cause of cardiovascular (CV) mor-
ality. The susceptibility to CAD is affected by the complex
nteraction of genomic and proteomic interactions. Prog-
ostic studies have shown that endothelial dysfunction with
decreased bioactivity of nitric oxide (NO) is associated
ith an increased rate of major adverse cardiovascular events
n patients with CAD, diabetes, peripheral arterial occlusive
isease, and arterial hypertension. Thus elucidating the role
f genes, whose products are involved in formation and
egradation of NO, a ubiquitous signalling molecule largely
esponsible for the maintenance of normal endothelial
unction, seems of major significance. It is clear that
ndothelial nitric oxide synthase (eNOS) has evolved to be
ightly controlled by co-translational and post-translational
ipid modifications, phosphorylation, multiple residues, and
egulated protein-protein interactions (1). Thus far no
rospective studies exist that simultaneously quantify alter-
tions of a single nucleotide in the deoxyribonucleic acid
equence, so-called single nucleotide polymorphism (SNP),
hat encode for eNOS and metabolites of NO in CAD
atients.
See page 1166
Three SNPs for eNOS have been described thus far:
ntron-4, Glu298Asp, and T786C SNPs. The GAG to
AT substitution in exon 7 (G894T) determines the
onservative replacement of glutamate with aspartate
Glu298Asp), which might cause a tight turn of the -helix
nd therefore an increased susceptibility to degradation.
he T786C SNP is located in the promoter region of the
NOS encoding gene. The significance of these SNPs is still
ontroversial (2). The conflicting results may be attributable
o different analytical approaches (3), to varying stabilization
f gene products in various vascular diseases (4), and most
mportantly, to the fact that most of the published reports
sed a cross-sectional rather than a prospective study design
*Editorials published in the Journal of American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.p
From the Department of Medicine I, Division of Cardiology, Pulmonary Diseases,
nd Vascular Medicine, UKA University Clinic, Aachen, Germany.nd the patient populations were rather small, raising the
ssue of several statistical bias.
In this issue of the Journal, Rossi et al. (5) reported on the
mpact of eNOS SNPs in 1,086 patients with CAD at high
V risk recruited from the prospective branch of the
ENICA (Genetic and Environmental Factors in Coro-
ary Artery Disease) study (5). The extent of CAD in large
oronary vessels was graded by the modified Duke Prog-
ostic Index. The investigators tested the hypothesis that
he G894T and T786C eNOS SNPs predict CV deaths in
his cohort. Genotyping was performed with a LightCycler
Roche, Milan, Italy) using melting curve analysis. The sum
f oxidative NO metabolites in plasma (NOx, that is nitrite
nd nitrate), nitrotyrosine, and the formation of free radicals
s a surrogate for mylo peroxidase activity were estimated
sing commercial enzyme-linked immunosorbent assay and
hotometric kits. The Glu298Asp according to SNP in
xon 7 (G894T), a conservative replacement, showed no
ffect. In a previous small cross-sectional study, Rossi et al.
5) had already shown that this SNP only affects the flow
esponse to acetylcholine in the forearm circulation of
ypertensive individuals through the interaction with
786C SNP, both being in a linkage disequilibrium. In the
resent study, the SNP T786C located in the eNOS gene
romoter had a significant effect on CV death-free survival,
ut not on plasma nitrite/nitrate levels.
The strength and unique character of the present study
5) is supported by several features: it is the first prospective
tudy showing an effect of the T786C SNP on survival in
igh-risk patients, even after control for other typical CV
isk factors. A large sample size with a high follow-up rate
f 98% was studied, providing adequate statistical power to
est the hypothesis. Coronary artery risk burden was quan-
ified in every single patient at study entry. Not only were
NPs analyzed, but also surrogate markers of the respective
ignalling pathways of the vascular wall. Previous medica-
ion with NO donors was considered. However, biochem-
cal analysis was done only in a small (but randomly
elected) subset of patients, and biochemical assays of
uestionable specificity were used. This may explain some
spects of the paradoxical finding that the T786 allele was
ssociated with increased CV risk, although surrogates of
O bioactivity such as NOx and nitrotyrosine were directed
n the opposite direction.
The steady-state concentration and thus the biological
ffects of NO are critically determined not only by its rate of
ormation, but also by its rate of decomposition (6). A series
f studies within recent years has unraveled mechanisms by
hich NO bioactivity in blood might be sustained. Circu-
ating NO pool comprises of various nitrosylated species and
he oxidative products nitrite and nitrate (7). The plasma
evels of nitrotyrosin compounds are influenced not only by
NOS activity but also by multiple enzymes involved in
he metabolism of reactive oxygen species. Therefore, this
arameter may not merely reflect changes caused by eNOS
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Editorial Comment September 19, 2006:1175–6xpression and activity. Although nitrate levels are affected
y a variety of eNOS-independent factors (6), plasma nitrite
eflects constitutive NOS activity in mammals (8). In the
resent study by Rossi et al. (5), only the sum of nitrite and
itrate was determined. Thus the high background level of
itrate may have masked directed changes of nitrite as a
aluable index of eNOS activity, and thus might explain
ome of the unexpected results. Apart from plasma, eryth-
ocytes have been shown to represent a major storage site of
itrite in human blood (9) and are capable of producing
ioactive amounts of NO through reduction of nitrite,
urther contributing to the circulating NO pool (10). Very
ecently these findings have been extended, showing that
rythrocytes express a functional eNOS (11). These recent
dvances should enable us now to perform a comprehensive
nalyses of the circulating NO pool in humans, together
ith analysis of SNPs for eNOS.
The scientific field of cardiac biomarkers is rapidly
rowing (12). A novel approach has evolved by using a
ultimarker strategy combining biochemical measures of
eart failure, ischemia, and inflammation (12). This strategy
as been broadened by measuring biochemical markers (12)
ogether with structural (13) and functional (14) markers for
ndothelial dysfunction and cardiovascular disease. The
resent study by Rossi et al. (5) offers the avenue for
eveloping new strategies in the scientific field of diagnostic
arkers of malign across the cardiovascular continuum.
Cardiovascular disease is the consequence of a complex
eries of pathophysiological events in genetically susceptible
ndividuals resulting in systemic and/or localized tissue
amage, ultimately leading to target organ failure, clinical
vents, or death. Endothelial dysfunction is a key event in
hese processes. Based on the present findings, a multiple-
evel marker strategy can be invented targeting specifically
athophysiological alterations along the eNOS pathway in
atients by measuring genetic, biochemical, functional, and
tructural markers in patients simultaneously. Such an
pproach could comprise the analysis of eNOS SNPs, a
omprehensive analysis of the circulating NO pool, mea-
urement of flow-mediated dilation, and intima-media
hickness. Because these analytical tools will become avail-ble for clinical routine in the very near future, a multiple-
evel marker strategy focusing on a single key signalling
athway to diagnose different stages of the complex and
olygenic cardiovascular diseases seems realistic very soon.
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